López-Cima M Felicitas, González-Arriaga Patricia, García-Castro Laura, Pascual Teresa, Marrón Manuel G, Puente Xose S, Tardón Adonina
Departamento de Medicina, Facultad de Medicina, Unidad de Epidemiología Molecular del Instituto Universitario de Oncología, Universidad de Oviedo, 33006 Oviedo, Spain.
BMC Cancer. 2007 Aug 16;7:162. doi: 10.1186/1471-2407-7-162.
Polymorphisms in DNA repair genes have been associated to repair DNA lesions, and might contribute to the individual susceptibility to develop different types of cancer. Nucleotide excision repair (NER), base excision repair (BER), and double-strand break repair (DSBR) are the main DNA repair pathways. We investigated the relationship between polymorphisms in two NER genes, XPC (poly (AT) insertion/deletion: PAT-/+) and XPD (Asp312Asn and Lys751Gln), the BER gene XRCC1 (Arg399Gln), and the DSBR gene XRCC3 (Thr241Met) and the risk of developing lung cancer.
A hospital-based case-control study was designed with 516 lung cancer patients and 533 control subjects, matched on ethnicity, age, and gender. Genotypes were determined by PCR-RFLP and the results were analysed using multivariate unconditional logistic regression, adjusting for age, gender and pack-years.
Borderline association was found for XPC and XPD NER genes polymorphisms, while no association was observed for polymorphisms in BER and DSBR genes. XPC PAT+/+ genotype was associated with no statistically significant increased risk among ever smokers (OR = 1.40; 95%CI = 0.94-2.08), squamous cell carcinoma (OR = 1.44; 95%CI = 0.85-2.44), and adenocarcinoma (OR = 1.72; 95%CI = 0.97-3.04). XPD variant genotypes (312Asn/Asn and 751Gln/Gln) presented a not statistically significant risk of developing lung cancer (OR = 1.52; 95%CI = 0.91-2.51; OR = 1.38; 95%CI = 0.85-2.25, respectively), especially among ever smokers (OR = 1.58; 95%CI = 0.96-2.60), heavy smokers (OR = 2.07; 95%CI = 0.74-5.75), and adenocarcinoma (OR = 1.88; 95%CI = 0.97-3.63). On the other hand, individuals homozygous for the XRCC1 399Gln allele presented no risk of developing lung cancer (OR = 0.87; 95%CI = 0.57-1.31) except for individuals carriers of 399Gln/Gln genotype and without family history of cancer (OR = 0.57; 95%CI = 0.33-0.98) and no association was found between XRCC3 Thr241Met polymorphism and lung cancer risk (OR = 0.92; 95%CI = 0.56-1.50), except for the 241Met/Met genotype and squamous cell carcinoma risk (OR = 0.47; 95%CI = 0.23-1.00).
In conclusion, we analysed the association between XPC, XPD, XRCC1, and XRCC3 polymorphisms and the individual susceptibility to develop lung cancer in the Spanish population, specifically with a highly tobacco exposed population. We attempt to contribute to the discovery of which biomarkers of DNA repair capacity are useful for screening this high-risk population for primary preventing and early detection of lung cancer.
DNA修复基因多态性与DNA损伤修复相关,可能影响个体患不同类型癌症的易感性。核苷酸切除修复(NER)、碱基切除修复(BER)和双链断裂修复(DSBR)是主要的DNA修复途径。我们研究了两种NER基因XPC(聚(AT)插入/缺失:PAT - / +)和XPD(Asp312Asn和Lys751Gln)、BER基因XRCC1(Arg399Gln)以及DSBR基因XRCC3(Thr241Met)的多态性与肺癌发生风险之间的关系。
设计了一项基于医院的病例对照研究,纳入516例肺癌患者和533例对照,根据种族、年龄和性别进行匹配。通过PCR - RFLP确定基因型,并使用多变量无条件逻辑回归分析结果,对年龄、性别和吸烟包年数进行校正。
发现XPC和XPD NER基因多态性存在临界关联,而BER和DSBR基因多态性未观察到关联。XPC PAT + / +基因型在曾经吸烟者(OR = 1.40;95%CI = 0.94 - 2.08)、鳞状细胞癌患者(OR = 1.44;95%CI = 0.85 - 2.44)和腺癌患者(OR = 1.72;95%CI = 0.97 - 3.04)中与无统计学意义的风险增加相关。XPD变异基因型(312Asn/Asn和751Gln/Gln)患肺癌的风险无统计学意义(OR分别为1.52;95%CI = 0.91 - 2.51和OR = 1.38;95%CI = 0.85 - 2.25),尤其是在曾经吸烟者(OR = 1.58;95%CI = 0.96 - 2.60)、重度吸烟者(OR = 2.07;95%CI = 0.74 - 5.75)和腺癌患者(OR = 1.88;95%CI = 0.97 - 3.63)中。另一方面,XRCC1 399Gln等位基因纯合个体患肺癌的风险无增加(OR = 0.87;95%CI = 0.57 - 1.31),但399Gln/Gln基因型且无癌症家族史的个体除外(OR = 0.57;95%CI = 0.33 - 0.98),且未发现XRCC3 Thr241Met多态性与肺癌风险之间存在关联(OR = 0.92;95%CI = 0.56 - 1.50),但241Met/Met基因型与鳞状细胞癌风险相关(OR = 0.47;95%CI = 0.23 - 1.00)。
总之,我们分析了西班牙人群中XPC、XPD、XRCC1和XRCC3多态性与个体患肺癌易感性之间的关联,特别是在高度暴露于烟草的人群中。我们试图为发现哪些DNA修复能力生物标志物可用于筛查该高危人群以进行肺癌的一级预防和早期检测做出贡献。